A Systems-Based Analysis of the CardioMEMS HF Sensor for Chronic Heart Failure Management
Table 1
Baseline descriptive characteristics.
Demographic information
Age
64.4 [14.8]
Male
52 (66.7%)
White
42 (53.8%)
Left ventricular ejection fraction >40%
20 (24.1%)
Ischemic cardiomyopathy
36 (46.2%)
Implantable cardiac defibrillator
51 (65.4%)
Left ventricular assist device
11 (14.1%)
NYHA class
III
76 (97.4%)
IV
2 (2.6%)
Medical comorbidities
Hypertension
47 (60.2%)
Coronary artery disease
38 (48.7%)
Diabetes mellitus
38 (48.7%)
Atrial fibrillation
46 (59.0%)
Chronic obstructive pulmonary disease
8 (10.3%)
Chronic kidney disease stage IV or V
13 (16.7%)
Medications
Beta-blocker
69 (88.5%)
ACE inhibitor/ARB
32 (41.0%)
Aldosterone antagonist
34 (43.6%)
Loop diuretic
67 (85.9%)
Angiotensin receptor-neprilysin inhibitor
6 (7.7%)
Organic nitrate
13 (16.7%)
Hydralazine
19 (24.4%)
Inotrope (home infusion)
8 (10.3%)
Hemodynamic analyses
Systolic blood pressure
114 [17.6]
Diastolic blood pressure
64 [11.5]
Heart rate
76 [11.9]
Baseline pulmonary artery diastolic pressure
24.7 [7.9]
Note: categorical data are presented as number (percent), and continuous data are presented as mean [standard deviation]. Data obtained at time of CardioMEMS sensor implant. NYHA: New York Heart Association; ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker.
